MHRA announces that it is confident that there are still huge benefits of the Oxford-AstraZeneca vaccine in preventing Covid-19 and serious disease.

However, due to a very small number of blood clots in younger people, those under the age of 30 will be offered Pfizer or Moderna instead.

The EU regulator has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Oxford-AstraZeneca jab but that the benefits of the Oxford-AstraZeneca jab overall outweigh side effects.

More soon.